Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2019 Feb 1.

Published in final edited form as: Oral Oncol. 2017 Dec 23;77:83–89. doi: 10.1016/j.oraloncology.2017.12.003

Table 3.

Patient characteristics of CD8 and CD4 cohorts

		CD8 Cohort			CD4 Cohort

		Negative	Positive	Chi-Squared	Negative	Positive	Chi-Squared

Gender	Male	56 (82%)	73 (84%)	0.80	64 (83%)	50 (83%)	0.97
Gender	Female	12 (18%)	14 (16%)	0.80	13 (17%)	10 (17%)	0.97

Subsite	Supraglottic	31 (46%)	32 (37%)	0.52	36 (47%)	20 (33%)	0.32
	Glottic	36 (53%)	54 (62%)		39 (51%)	39 (65%)
	Subglottic	0 (0%)	0 (0%)		1 (1%)	0 (0%)
	Unknown	1 (1%)	1 (1%)		1 (1%)	1 (2%)

Initial stage	I–II	34 (50%)	49 (56%)	0.12	46 (54%)	31 (53%)	0.99
	III–IV	32 (47%)	27 (31%)		34 (40%)	23 (40%)
	Unknown	2 (3%)	11 (13%)		5 (6%)	4 (7%)

Initial T	T1–2	37 (54%)	53 (61%)	0.09	49 (58%)	35 (60%)	0.68
	T3–4	29 (43%)	23 (26%)		31 (36%)	19 (33%)
	Unknown	2 (3%)	11 (13%)		5 (6%)	4 (7%)

Initial N	N0	51 (75%)	66 (76%)	0.19	63 (74%)	46 (79%)	0.28
	N+	15 (22%)	11 (13%)		18 (21%)	8 (14%)
	Unknown	2 (3%)	10 (11%)		4 (5%)	4 (7%)

Recurrent stage	I–II	22 (32%)	26 (30%)	0.74	28 (33%)	20 (34%)	0.85
Recurrent stage	III–IV	46 (68%)	61 70%)	0.74	57 (67%)	38 (66%)	0.85

Recurrent T	TI–2	26 (38%)	29 (33%)	0.53	30 (35%)	24 (41%)	0.46
Recurrent T	T3–4	42 (62%)	58 (66%)	0.53	55 (65%)	34 (59%)	0.46

Recurrent N	N0	49 (72%)	63 (72%)	0.96	60 (71%)	46 (79%)	0.24
Recurrent N	N+	19 (28%)	24 (28%)	0.96	25 (29%)	12 (21%)	0.24

Smoker	Yes	64 (94%)	86 (99%)	0.10	74 (96%)	59 (98%)	0.44
Smoker	No	4 (6%)	1 (1%)	0.10	3 (4%)	1 (2%)	0.44

Alcohol	Yes	43 (63%)	62 (71%)	0.07	52 (68%)	42 (70%)	0.70
	No	24 (35%)	19 (22%)		20 (26%)	16 (27%)
	Unknown	1 (1%)	6 (7%)		5 (6%)	2 (3%)